[{"data":1,"prerenderedAt":60},["ShallowReactive",2],{"post-agonistas-glp-1-obesidad-popularidad-dudas-seguridad":3},{"id":4,"documentId":5,"Title":6,"Author":7,"URL":8,"Publication_date":9,"Hashtags":10,"Content":11,"createdAt":12,"updatedAt":13,"publishedAt":14,"Summary":15,"title_Url":16,"specialty":17,"Image":18},209,"kp622dvo3gnb08u001qulqs6","Agonistas del receptor del péptido similar al glucagón tipo 1 para la obesidad: creciente popularidad acompañada de crecientes interrogantes sobre su seguridad","Ariana M. Chao","https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004871","2026-01-14","#Medicina #Obesidad #GLP1 #SaludPublica #SeguridadMedicamentos","Los medicamentos basados en el péptido similar al glucagón tipo 1 (GLP-1), como el semaglutida y el tirzepatida, han transformado el tratamiento de la obesidad. Sin embargo, el aumento en su uso genera preocupaciones sobre los efectos secundarios, los resultados a largo plazo y los productos no regulados. Garantizar un acceso seguro requiere supervisión, monitoreo y atención clínica coordinada.\n\nEn esta Perspectiva, Ariana Chao, Adam Gilden y Thomas Wadden analizan por qué, junto con la creciente popularidad de los medicamentos basados en GLP-1 para la obesidad, también existen inquietudes sobre efectos adversos, consecuencias a largo plazo y productos no regulados.","2026-01-21T15:12:43.851Z","2026-01-22T03:42:29.946Z","2026-01-22T03:42:29.967Z","La transformación del tratamiento de la obesidad mediante medicamentos GLP-1 conlleva retos regulatorios y de seguridad. Ante el aumento en su prescripción, se hace indispensable una supervisión clínica coordinada para mitigar efectos secundarios y garantizar un acceso seguro a estas terapias de nueva generación.","agonistas-glp-1-obesidad-popularidad-dudas-seguridad","Endocrinología",{"id":19,"documentId":20,"name":21,"alternativeText":22,"caption":22,"width":23,"height":23,"formats":24,"hash":55,"ext":28,"mime":29,"size":56,"url":57,"previewUrl":22,"provider":58,"provider_metadata":22,"createdAt":59,"updatedAt":59,"publishedAt":59},79,"t14qsiac5lfhpe2yr6jzjdvr","image.png",null,1024,{"thumbnail":25,"small":34,"medium":41,"large":48},{"name":26,"hash":27,"ext":28,"mime":29,"path":22,"width":30,"height":30,"size":31,"sizeInBytes":32,"url":33},"thumbnail_image.png","thumbnail_image_77b71dd644",".png","image/png",156,46.04,46038,"/uploads/thumbnail_image_77b71dd644.png",{"name":35,"hash":36,"ext":28,"mime":29,"path":22,"width":37,"height":37,"size":38,"sizeInBytes":39,"url":40},"small_image.png","small_image_77b71dd644",500,366.11,366113,"/uploads/small_image_77b71dd644.png",{"name":42,"hash":43,"ext":28,"mime":29,"path":22,"width":44,"height":44,"size":45,"sizeInBytes":46,"url":47},"medium_image.png","medium_image_77b71dd644",750,790.31,790305,"/uploads/medium_image_77b71dd644.png",{"name":49,"hash":50,"ext":28,"mime":29,"path":22,"width":51,"height":51,"size":52,"sizeInBytes":53,"url":54},"large_image.png","large_image_77b71dd644",1000,1265.48,1265483,"/uploads/large_image_77b71dd644.png","image_77b71dd644",286.37,"/uploads/image_77b71dd644.png","local","2026-01-21T15:12:43.537Z",1777183248826]